Structure Therapeutics (NASDAQ:GPCR) Trading Down 10.7% – Should You Sell?

Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) shares traded down 10.7% on Thursday . The stock traded as low as $73.97 and last traded at $72.5320. 378,493 shares were traded during trading, a decline of 67% from the average session volume of 1,144,681 shares. The stock had previously closed at $81.26.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on the company. The Goldman Sachs Group raised Structure Therapeutics to a “strong-buy” rating in a report on Tuesday, January 20th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Structure Therapeutics in a research report on Thursday, January 22nd. Piper Sandler reaffirmed an “overweight” rating on shares of Structure Therapeutics in a research report on Tuesday, October 28th. JPMorgan Chase & Co. upped their price objective on Structure Therapeutics from $65.00 to $105.00 and gave the stock an “overweight” rating in a research report on Thursday, January 22nd. Finally, Jefferies Financial Group set a $125.00 price objective on shares of Structure Therapeutics and gave the company a “buy” rating in a research report on Thursday, December 11th. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, Structure Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $104.45.

Structure Therapeutics Stock Down 6.3%

The firm’s fifty day simple moving average is $69.25 and its 200-day simple moving average is $40.45. The company has a market cap of $4.62 billion, a PE ratio of -62.09 and a beta of -2.06.

Structure Therapeutics (NASDAQ:GPCR) last announced its quarterly earnings data on Thursday, November 6th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.36) by ($0.01). On average, analysts predict that Structure Therapeutics Inc. Sponsored ADR will post -0.82 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the business. CWM LLC raised its stake in shares of Structure Therapeutics by 35.2% during the fourth quarter. CWM LLC now owns 480 shares of the company’s stock valued at $33,000 after purchasing an additional 125 shares during the period. PNC Financial Services Group Inc. grew its position in shares of Structure Therapeutics by 9.4% during the 3rd quarter. PNC Financial Services Group Inc. now owns 4,828 shares of the company’s stock valued at $135,000 after buying an additional 413 shares during the last quarter. China Universal Asset Management Co. Ltd. raised its position in shares of Structure Therapeutics by 4.3% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 10,888 shares of the company’s stock worth $757,000 after purchasing an additional 444 shares during the period. Assetmark Inc. lifted its stake in Structure Therapeutics by 39.9% in the second quarter. Assetmark Inc. now owns 2,877 shares of the company’s stock valued at $60,000 after buying an additional 820 shares during the last quarter. Finally, EverSource Wealth Advisors LLC lifted its position in Structure Therapeutics by 530.0% in the 3rd quarter. EverSource Wealth Advisors LLC now owns 1,071 shares of the company’s stock valued at $30,000 after purchasing an additional 901 shares during the last quarter. Hedge funds and other institutional investors own 91.78% of the company’s stock.

About Structure Therapeutics

Structure Therapeutics (NASDAQ:GPCR) is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.